A Clinical Approach to existing and emerging therapeutics in Neuromyelitis Optica Spectrum Disorder
HYF Yong, JM Burton - Current Neurology and Neuroscience Reports, 2023 - Springer
HYF Yong, JM Burton
Current Neurology and Neuroscience Reports, 2023•SpringerAbstract Purpose of Review Neuromyelitis optica spectrum disorder (NMOSD) is a rare but
highly disabling disease of the central nervous system. Unlike multiple sclerosis, disability in
NMOSD occurs secondary to relapses that, not uncommonly, lead to blindness, paralysis,
and death. Recently, newer, targeted immunotherapies have been trialed and are now in the
treatment arsenal. We have endeavoured to evaluate the current state of NMOSD
therapeutics. Recent Findings This review provides a pragmatic evaluation of recent clinical …
highly disabling disease of the central nervous system. Unlike multiple sclerosis, disability in
NMOSD occurs secondary to relapses that, not uncommonly, lead to blindness, paralysis,
and death. Recently, newer, targeted immunotherapies have been trialed and are now in the
treatment arsenal. We have endeavoured to evaluate the current state of NMOSD
therapeutics. Recent Findings This review provides a pragmatic evaluation of recent clinical …
Purpose of Review
Neuromyelitis optica spectrum disorder (NMOSD) is a rare but highly disabling disease of the central nervous system. Unlike multiple sclerosis, disability in NMOSD occurs secondary to relapses that, not uncommonly, lead to blindness, paralysis, and death. Recently, newer, targeted immunotherapies have been trialed and are now in the treatment arsenal. We have endeavoured to evaluate the current state of NMOSD therapeutics.
Recent Findings
This review provides a pragmatic evaluation of recent clinical trials and post-marketing data for rituximab, inebilizumab, satralizumab, eculizumab, and ravalizumab, contrasted to older agents. We also review contemporary issues such as treatment in the context of SARS-CoV2 infection and pregnancy.
Summary
There has been a dramatic shift in NMOSD morbidity and mortality with earlier and improved disease recognition, diagnostic accuracy, and the advent of more effective, targeted therapies. Choosing a maintenance therapy remains nuanced depending on patient factors and accessibility. With over 100 putative agents in trials, disease-free survival is now a realistic goal for NMOSD patients.
Springer
以上显示的是最相近的搜索结果。 查看全部搜索结果